ERBB2 and neoplasm: More specifically, HER2‐positive/ER‐negative tumours are more likely to present with high histologic grade and higher tumour stage, less likely to first relapse in bone, and more likely to recur in brain than HER2‐positive/HR‐positive tumours [63].